Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,793 | 112 | 96.7% |
| Education | $61.57 | 2 | 3.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $336.35 | 18 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $283.75 | 15 | $0 (2024) |
| OPKO Pharmaceuticals, LLC | $210.01 | 16 | $0 (2022) |
| Relypsa, Inc. | $176.13 | 12 | $0 (2020) |
| Amgen Inc. | $129.49 | 8 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $106.22 | 6 | $0 (2023) |
| Mallinckrodt LLC | $102.41 | 6 | $0 (2018) |
| GlaxoSmithKline, LLC. | $80.71 | 5 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $68.86 | 3 | $0 (2023) |
| Aurinia Pharma U.S., Inc. | $65.70 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $150.19 | 8 | AstraZeneca Pharmaceuticals LP ($96.95) |
| 2023 | $393.74 | 21 | Bayer Healthcare Pharmaceuticals Inc. ($88.94) |
| 2022 | $214.94 | 13 | AstraZeneca Pharmaceuticals LP ($61.05) |
| 2021 | $169.04 | 11 | GlaxoSmithKline, LLC. ($65.64) |
| 2020 | $82.74 | 6 | Relypsa, Inc. ($26.78) |
| 2019 | $353.62 | 22 | OPKO Pharmaceuticals, LLC ($89.33) |
| 2018 | $250.38 | 17 | Relypsa, Inc. ($78.41) |
| 2017 | $240.41 | 16 | Mallinckrodt LLC ($70.94) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 5 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/18/2017 | Genentech USA, Inc. | Rituxan (Biological) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: BioOncology/Immunology | ||||||
| 08/07/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 08/03/2017 | Amgen Inc. | Sensipar (Drug) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Nephrology | ||||||
| 06/27/2017 | OPKO Pharmaceuticals, LLC | Rayaldee (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Hyperparathyroidism | ||||||
| 05/26/2017 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: NEPHROLOGY | ||||||
| 05/03/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 04/13/2017 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: NEPHROLOGY | ||||||
| 03/31/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 03/22/2017 | Mallinckrodt LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 03/09/2017 | Amgen Inc. | Parsabiv (Biological), Sensipar | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: Nephrology | ||||||
| 03/08/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: Hyperkalemia | ||||||
| 01/25/2017 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Food and Beverage | In-kind items and services | $12.11 | General |
| Category: NEPHROLOGY | ||||||
| 01/24/2017 | Takeda Pharmaceuticals America, Inc. | Uloric (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: Gout/Rheumatology | ||||||
| 01/17/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 6,268 | 9,687 | $2.1M | $295,587 |
| 2022 | 43 | 5,952 | 9,976 | $969,699 | $264,876 |
| 2021 | 42 | 6,469 | 13,075 | $1.1M | $314,624 |
| 2020 | 42 | 6,486 | 14,205 | $1.3M | $352,014 |
All Medicare Procedures & Services
170 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 29 | 207 | $405,637 | $54,449 | 13.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 455 | 591 | $414,917 | $50,409 | 12.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 185 | 509 | $336,581 | $45,674 | 13.6% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 371 | 517 | $128,051 | $20,768 | 16.2% |
| 82306 | Vitamin d-3 level | Office | 2023 | 298 | 394 | $69,974 | $11,352 | 16.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 70 | 71 | $68,441 | $9,045 | 13.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 44 | 196 | $67,397 | $9,025 | 13.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 87 | 138 | $60,643 | $8,313 | 13.7% |
| 82610 | Cystatin c (enzyme inhibitor) level | Office | 2023 | 319 | 421 | $46,782 | $7,575 | 16.2% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 47 | 197 | $52,244 | $6,986 | 13.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $52,986 | $6,562 | 12.4% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 38 | 161 | $42,137 | $5,669 | 13.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 482 | 671 | $31,282 | $5,055 | 16.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 26 | 32 | $37,834 | $4,928 | 13.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 397 | 577 | $10,386 | $4,832 | 46.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 38 | $37,454 | $4,679 | 12.5% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 256 | 256 | $25,682 | $4,325 | 16.8% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 14 | 18 | $29,277 | $4,013 | 13.7% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 478 | 670 | $19,802 | $3,761 | 19.0% |
| 80069 | Kidney function blood test panel | Office | 2023 | 315 | 438 | $22,811 | $3,704 | 16.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 289 | 355 | $22,493 | $3,637 | 16.2% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 14 | 580 | $28,710 | $3,534 | 12.3% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 469 | 650 | $20,202 | $3,275 | 16.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 22 | 38 | $15,119 | $2,072 | 13.7% |
| 84550 | Uric acid level, blood | Office | 2023 | 346 | 458 | $12,421 | $2,013 | 16.2% |
About Dr. Stuart Ginther, M.D
Dr. Stuart Ginther, M.D is a Nephrology healthcare provider based in Chattanooga, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194776799.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stuart Ginther, M.D has received a total of $1,855 in payments from pharmaceutical and medical device companies, with $150.19 received in 2024. These payments were reported across 114 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($1,793).
As a Medicare-enrolled provider, Ginther has provided services to 25,175 Medicare beneficiaries, totaling 46,943 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 170 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology
- Location Chattanooga, TN
- Active Since 05/16/2006
- Last Updated 05/28/2010
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1194776799
Products in Payments
- FARXIGA (Drug) $221.14
- Veltassa (Drug) $189.16
- ACTHAR (Biological) $171.27
- SAMSCA (Drug) $170.52
- JYNARQUE (Drug) $165.83
- Rayaldee (Drug) $151.71
- Kerendia (Drug) $106.22
- BENLYSTA (Biological) $80.71
- LUPKYNIS (Drug) $65.70
- LOKELMA (Drug) $62.61
- RAYALDEE (Drug) $58.30
- Parsabiv (Biological) $49.55
- ULTOMIRIS (Biological) $34.76
- Parsabiv (Drug) $33.48
- Edarbi (Drug) $30.67
- Velphoro (Drug) $29.51
- Rituxan (Biological) $29.45
- TAVNEOS (Drug) $29.03
- KRYSTEXXA (Drug) $18.62
- Sensipar (Drug) $17.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Chattanooga
Rohit Gupta, M.d, M.D
Nephrology — Payments: $10,529
Hans Yehnert, Md, MD
Nephrology — Payments: $5,326
Nilesh Patel, M.d, M.D
Nephrology — Payments: $3,184
John Mccarley, M.d, M.D
Nephrology — Payments: $2,939
Brant Holt, Md, MD
Nephrology — Payments: $2,929
Mandeep Grewal, Md, MD
Nephrology — Payments: $2,449